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Drug-eluting stents (DES) have markedly reduced restenosis rates compared 
with bare metal  stents (BMS) in controlled randomized trials. Concerns have 
been raised about a possibly increased incidence of stent thrombosis (ST) 
after discontinuation of dual antiplatelet treatment compared with BMS. 
While a restenosis is  relatively benign process , this serious complication is an 
issue because mortality of such event i s reaching almost 50%. Among well 
recognized predictors of late stent thrombosis (delayed endothelisation, renal 
failure, bifurcation lesions, diabetes, premature antiplatelet therapy 
discontinuation, slow thrombus disappearance),  the stent under expansion and 
stent deployment technique are also considered to be a contributor for 
development of late stent thrombosis . There was a paucity of data regarding 
the IVUS guidance during DES implantation.  The aim of this study was to  
assess the role of IVUS guidance during implantation of DES on longterm 
outcome in patients with high clinical and angiographic risk profile.  
Methods: Between January 2004 and December 2005, 2110 patients underwent 
percutaneous coronary intervention, including 276 patients (13%) who were 
treated with drug-eluting stents. At the 6-month follow-up, 273 patients 
remained event-free and of these, have been completed the 12-month and 18-
month follow-ups and have been enrolled in the analysis. Dual antiplatelet  
treatment was administered for 6 months in all patients. In the second phase 
of the project we have analyse two hunderd and ten patients were r andomly 
assigned 1:1 to receive DES either with or without the IVUS guidance. At 18-
month follow-up, the rates of major adverse cardiac events (MACEs) (death , 
myocardial  infarction, and reintervention) were assessed in both groups with 
special attention to possible LST. Stent thrombosis was classified according 
to Academic Research Consortium (ARC).  
Results At the 18-month follow-up, stent thrombosis had occurred in 10 
patients (5.8%), resulting in five sudden deaths and five target -vessel 
nonfatal myocardial  infarctions. The majority (80%) of the events had 
developed within 7–12 months. The larger stent area and left main 
interventions were significantly associated with stent thrombosis (P= 0.031 
and P =0.001, respectively).   At the 18-month follow-up, there was no 
significant difference between both groups regarding MACE (11% vs. 12%; p  
= NS). Stent thrombosis has occurred in 4% in the group with and in 6%; p  = 
NS in the group without the IVUS guidance.  
Our study confirmed worrisome results concerning d rug-eluting stent 
thrombosis after the discontinuation of dual antiplatelet treatment. The rate of 
stent thrombosis-related events in our high -risk cohort of patiens reached 
almost 6% with a 50% mortality.  ln our randomized trial we failed to 
demonstrate the superiority of the IVUS guidance during DES implantation 
over standard high-pressure postdilatation. However we conf irmed worrisome 
results concerning DES thrombosis after discontinuation of dual antiplatelet-
treatment with documented stent thrombosis.  
